AMPE - Ampio Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
2.40
-0.04 (-1.64%)
As of 10:03AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.44
Open2.46
Bid0.00 x 900
Ask0.00 x 1000
Day's Range2.38 - 2.47
52 Week Range0.38 - 4.95
Volume65,898
Avg. Volume734,400
Market Cap207.17M
Beta1.10
PE Ratio (TTM)N/A
EPS (TTM)-0.39
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    Ampio provides a Link to New Publication on the Mechanism of Action for Ampion™

    ENGLEWOOD, Colo., July 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a basic science manuscript entitled "The Anti-Inflammatory Effect of LMWF5A and N-Acetyl Kynurenine on Macrophages: Involvement of Aryl Hydrocarbon Receptor in Mechanism of Action" authored by Dr. Bar-Or and prominent clinicians has been published online in Biochemistry and Biophysics Reports. Dr. David Bar-Or, Ampio's CSO explained: "This biochemical research uncovered an important part of the mechanism of action of Ampion™ or the low molecular weight fraction of 5% human serum albumin (LMWF5A). Here, we show that Ampion significantly decreases the release of pro-inflammatory biomarkers from LPS-stimulated macrophages and that one of the known components of Ampion (N-acetyl kynurenine or NAK) also decreased these biomarkers When an inhibitor of the aryl hydrocarbon receptor (AhR) was included, the anti-inflammatory effect of Ampion was partially blocked while the effect of NAK was completely prevented.

  • ACCESSWIRE20 days ago

    Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.

  • PR Newswire22 days ago

    Ampio Reports New Publication on the Mechanisms of Action for Ampion™

    ENGLEWOOD, Colo., June 27, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a basic science manuscript entitled "The Anti-Inflammatory Effect of LMWF5A and N-Acetyl Kynurenine on Macrophages: Involvement of Aryl Hydrocarbon Receptor in Mechanism of Action" has been accepted for publication in Biochemistry and Biophysics Reports. Dr. David Bar-Or, Ampio's CSO explained, "This biochemical research uncovered an important part of the mechanism of action of Ampion™ or the low molecular weight fraction of 5% human serum albumin (LMWF5A).

  • ACCESSWIRE24 days ago

    Today's Research Reports on Stocks to Watch: bluebird and Ampio Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / bluebird shares were in the red on Friday, retreating after several days of gains after an Evercore ISI analyst upgrade the stock to "outperform" and ...

  • PR Newswirelast month

    Ampio Provides Scientific Update and Links to Peer Review Publications

    ENGLEWOOD, Colo., June 5, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced two peer-reviewed articles on the clinical application of Ampion™ are now available online. "Peer-reviewed journals are an important part of the scientific process, which requires intensive scrutiny by other experts in the field of any manuscript submitted before publication. Ampion™ is the 'Low Molecular Weight Fraction of 5% human serum Albumin' (LMWF-5A) that is in development to treat severe osteoarthritis of the knee (OAK).

  • PR Newswire2 months ago

    Ampio Updates Regulatory and IP Activities

    The Company and the FDA have agreed to a July 2018 meeting to continue their discussions on the BLA submission being prepared for Ampion™ as a treatment of the signs and symptoms of severe (KL4) osteoarthritis-of-the- knee (OAK). Ampio was awarded US patent (9,956,217 B2) titled: "Treatment of Joint conditions" that provides method protection, until the year 2035, for multiple injections of Ampion™. This is supported by the fully enrolled Open-Label Extension (OLE) study for the assessment of the clinical safety for long-term treatment with Ampion (up to 5 yearly injections) that will conclude in 2019 and the completed (published) 3 injections trial (STRUT or AP-007).

  • ACCESSWIRE2 months ago

    Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • PR Newswire2 months ago

    Ampio Updates Scientific presentations and publications on Ampion™

    ENGLEWOOD, Colo., May 22, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a poster presentation on the mechanism of action of a component of Ampion™ will be presented at AAST and the most recent study of Ampion treatment of Severe Osteoarthritis of the Knee ( AP-007-B) has been accepted for publication by PSS.

  • PR Newswire2 months ago

    Ampio Provides Corporate Update

    During Q1, the Company received a total of $3.1 million from investor warrants and stock options being exercised. Discussions with the FDA are ongoing to address FDA questions and provide the company's responses, as the Agency encourages companies to discuss all facets of regulatory filing, including clinical results, labeling, Chemistry, Manufacturing and Controls (CMC), and other aspects of the development process prior to filing their BLA in order to reduce the possibility of receiving a Refusal to File (RTF) notification.

  • PR Newswire3 months ago

    The Pivotal Trial Results on Ampion™ (AP-003-C) Was Accepted for Publication in a Peer-Reviewed Medical Journal

    ENGLEWOOD, Colo., May 2, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the publication entitled: "Intra-articular injection of the anti-inflammatory compound LMWF-5A (Ampion™) in adults with severe osteoarthritis: a double-blind prospective randomized controlled multicenter safety and efficacy trial" authored by Dr. Brian Cole, MD, Kristin Salottolo MPH and Dr. David Bar-Or, MD was accepted for publication to the peer-reviewed journal "Patient Safety in Surgery".

  • Who Really Owns Ampio Pharmaceuticals Inc (NYSEMKT:AMPE)?
    Simply Wall St.3 months ago

    Who Really Owns Ampio Pharmaceuticals Inc (NYSEMKT:AMPE)?

    In this article, I’m going to take a look at Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • How Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Can Impact Your Portfolio Volatility
    Simply Wall St.3 months ago

    How Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Can Impact Your Portfolio Volatility

    If you are a shareholder in Ampio Pharmaceuticals Inc’s (AMEX:AMPE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • PR Newswire3 months ago

    Ampio Updates Regulatory, Clinical and NYSE Activities

    ENGLEWOOD, Colo., April 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has begun preliminary discussions with the Food and Drug Administration on details of the Biologics License Application (BLA) submission process for Ampion™, a treatment for severe osteoarthritis-of-the-knee. Second, Nature Biotechnology, a respected journal, with a very high impact factor, has published a commentary on Ampion, our lead drug. Finally, Ampio has received a notification letter from the New York Stock Exchange confirming that Ampio is now in full compliance with their listing requirements.

  • PR Newswire4 months ago

    Ampio Updates Regulatory and Clinical Activities

    ENGLEWOOD, Colo., April 3, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has retained PAREXEL® (www.parexel.com/) to assist in preparing and presenting the Biologics License Application (BLA) for Ampion™ for the treatment of osteoarthritis-of-the-knee (OAK) to the FDA. Mr. Macaluso, Ampio's CEO, noted that "PAREXEL is particularly suited to assist the Company in the preparation and presentation of the BLA to the FDA because their CRO Division helped design and manage the successful pivotal Phase III clinical trial.

  • PR Newswire4 months ago

    Evidence for Delay of Total Knee Replacement (TKR) for Patients with Severe Osteoarthritis of the Knee Receiving Three Intra-articular (IA) Ampion™ Injections

    ENGLEWOOD, Colo. , March 26, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced partial results of a follow-up (3.4-3.7 years), double-blind, randomized, controlled trial ...

  • PR Newswire4 months ago

    Ampio Pharmaceuticals Provides Corporate Update Following Conference Call

    Included below are highlighted disclosures from the corporate update and filed Annual report on Form 10K. Primary endpoint achieved statistical significance when 71% of Ampion-treated patients met the OARSI responder criteria, which exceeded the historically based standard control for a meaningful treatment in severe OAK (p

  • PR Newswire4 months ago

    Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST

    ENGLEWOOD, Colo. , March 6, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:  AMPE) hosting a conference call Wednesday, March 7th at 5:00 pm EST . Participants are invited to dial in using ...

  • Here's Why Ampio Pharmaceuticals Dropped as Much as 18.8% Today
    Motley Fool5 months ago

    Here's Why Ampio Pharmaceuticals Dropped as Much as 18.8% Today

    What goes up must come down.

  • Is Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Still A Cheap Healthcare Stock?
    Simply Wall St.5 months ago

    Is Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Still A Cheap Healthcare Stock?

    Ampio Pharmaceuticals Inc (AMEX:AMPE), a US$233.14M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...

  • Simply Wall St.6 months ago

    Is Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) CEO Salary Justified?

    Mike Macaluso is the CEO of Ampio Pharmaceuticals Inc (AMEX:AMPE), which has recently grown to a market capitalization of $220.23M. Understanding how CEOs are incentivised to run and grow theirRead More...

  • PR Newswire6 months ago

    Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions

    ENGLEWOOD, Colo., Jan. 16, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported a heavy schedule of meetings throughout the four-day conference, predominately with significant pharmaceutical companies discussing the successful clinical results of the company's second pivotal phase III trial announced Dec. 14, 2017. The discussions also explored whether Ampion™ could provide not only relief of signs and symptoms of osteoarthritis of the knee (OAK) but also be "a disease-modifying drug" for this condition. David Bar-Or, M.D., Ampio's CSO explained: "OAK, over time, causes progressive loss of cartilage in the knee, which is one of the reasons for limited joint function and chronic pain in this condition (although cartilage has no nerve endings, sub chondral bone does).

  • What Does Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Ownership Structure Look Like?
    Simply Wall St.6 months ago

    What Does Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Ownership Structure Look Like?

    In this analysis, my focus will be on developing a perspective on Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...

  • PR Newswire6 months ago

    Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders

    ENGLEWOOD, Colo. , Jan. 8, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces that the company will be updating potential collaborators and attending shareholders at the J.P. Morgan ...